CD274 and neoplasm: Immune checkpoint inhibitors targeting PD-1/PD-L1, and CTLA-4 have made remarkable forward in various human malignancies, while most patients are reported to obtain a short-term complete or partial remission following treatment, the majority of patients eventually raised drug resistance and succumb to tumor recurrence (4, 5).